Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of MBS303 in relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma
CTR20230423Phase 2Active
- Sponsor
- Mabworks Biotech
- Start
- Jul 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MBS303 in mature B-cell lymphoma, sponsored by Mabworks Biotech. Started Jul 2023; status: active.
02
Drugs
MBS303
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on CTR20230423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230423.